Cyclerion

our current portfolio includes novel clinical-stage assets, namely praliciguat and olinciguat, as well as multiple research stage molecules. praliciguat is a systemic sgc stimulator that is exclusively licensed to akebia and is being advanced in rare kidney disease. olinciguat is a vascular sgc stimulator that cyclerion intends to develop itself or out-license for cardiovascular diseases. concurrently, we are also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. in addition, cyclerion holds 10 percent equity ownership in tisento therapeutics as part of an asset purchase agreement in which tisento acquired the brain-penetrant sgc stimulators zagociguat and cy3018.